Toxicity evaluation of antiglaucoma drugs using stratified human cultivated corneal epithelial sheets

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 9, 2012, Pages 5154-5160

  Nakagawa, Suguru ^a,b   Usui, Tomohiko ^a   Yokoo, Seiichi ^a   Omichi, Sachiko ^a,c   Kimakura, Mikiko ^a   Mori, Yosai ^d   Miyata, Kazunori ^d   Aihara, Makoto ^a   Amano, Shiro ^a   Araie, Makoto ^a,e  

^a UNIVERSITY OF TOKYO   (Japan)

^b Tokyo Metropolitan Institute of Gerontology   (Japan)

^c JR Tokyo General Hospital   (Japan)

^d Miyata Eye Hospital   (Japan)

^e The Mutualaid Association of Public School Teachers)   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; BENZALKONIUM CHLORIDE; BENZOIC ACID; CARBOXYFLUORESCEIN; LATANOPROST; LATANOPROST PLUS TIMOLOL; POLIDRONIUM CHLORIDE; PROTEIN ZO1; TAFLUPROST; TIMOLOL PLUS TRAVOPROST; TRAVOPROST;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CORNEA EPITHELIUM; GLAUCOMA; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; PERMEABILITY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIHYPERTENSIVE AGENTS; BENZALKONIUM COMPOUNDS; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; CELLS, CULTURED; CULTURE MEDIA, SERUM-FREE; DRUG COMBINATIONS; EPITHELIUM, CORNEAL; FLUORESCEINS; FLUORESCENT DYES; GLAUCOMA; HUMANS; MEMBRANE PROTEINS; OPHTHALMIC SOLUTIONS; PHOSPHOPROTEINS; PRESERVATIVES, PHARMACEUTICAL; PROSTAGLANDINS F, SYNTHETIC; TIMOLOL;

EID: 84864705262     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-9685     Document Type: Article

References (51)

1. Furrer P, Mayer JM, Gurny R. Ocular tolerance of preservatives and alternatives. Eur J Pharm Biopharm. 2002; 53: 263-280.
2. Hamard P, Blondin C, Debbasch C, Warnet JM, Baudouin C, Brignole F. In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells. Graefes Arch Clin Exp Ophthalmol. 2003; 241: 1037-1043.
3. Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci. 2004; 45: 1360-1368.
4. Whitson JT, Cavanagh HD, Lakshman N, Petroll WM. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Adv Ther. 2006; 23: 663-671.
5. Yee RW, Norcom EG, Zhao XC. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system. Adv Ther. 2006; 23: 511-519.
6. McCarey B, Edelhauser H. In vivo corneal epithelial permeability following treatment with prostaglandin analogs [correction of analoges] with or without benzalkonium chloride. J Ocul Pharmacol Ther. 2007; 23: 445-451.
7. Yee RW. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. Curr Opin Ophthalmol. 2007; 18: 134-139.
8. Guo Y, Satpathy M, Wilson G, Srinivas SP. Benzalkonium chloride induces dephosphorylation of Myosin light chain in cultured corneal epithelial cells. Invest Ophthalmol Vis Sci. 2007; 48: 2001-2008.
9. Malvitte L, Montange T, Vejux A, et al. Measurement of inflammatory cytokines by multicytokine assay in tears of patients with glaucoma topically treated with chronic drugs. Br J Ophthalmol. 2007; 91: 29-32.
10. Baudouin C, Riancho L, Warnet JM, Brignole F. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latano-prost. Invest Ophthalmol Vis Sci. 2007; 48: 4123-4128.
11. Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea. 2008; 27: 339-343.
12. Ayaki M, Yaguchi S, Iwasawa A, Koide R. Cytotoxicity of ophthalmic solutions with and without preservatives to human corneal endothelial cells, epithelial cells and conjunc-tival epithelial cells. Clin Experiment Ophthalmol. 2008; 36: 553-559.
13. Liang H, Baudouin C, Pauly A, Brignole-Baudouin F. Conjunc-tival and corneal reactions in rabbits following short-and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. Br J Ophthalmol. 2008; 92: 1275-1282.
14. Epstein SP, Chen D, Asbell PA. Evaluation of biomarkers of inflammation in response to benzalkonium chloride on corneal and conjunctival epithelial cells. J Ocul Pharmacol Ther. 2009; 25: 415-424.
15. Ammar DA, Kahook MY. The effects of combination glaucoma medications on ocular surface epithelial cells. Adv Ther. 2009; 26: 970-975.
16. Liang H, Baudouin C, Faure MO, Lambert G, Brignole-Baudouin F. Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prosta-glandins: an in vivo toxicity assay. Mol Vis. 2009; 15: 1690-1699.
17. Baudouin C, Labbe A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010; 29: 312-334.
18. Whitson JT, Trattler WB, Matossian C, Williams J, Hollander DA. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2010; 26: 287-292.
19. Wilhelmus KR. The Draize eye test. Surv Ophthalmol. 2001; 45: 493-515.
20. Curren RD, Harbell JW. Ocular safety: a silent (in vitro) success story. Altern Lab Anim. 2002; 30: 69-74.
21. Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F. In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimato-prost on conjunctiva-derived epithelial cells. Invest Ophthal-mol Vis Sci. 2005; 46: 4594-4599.
22. Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci. 2005; 46: 2444-2450.
23. Brasnu E, Brignole-Baudouin F, Riancho L, Guenoun JM, Warnet JM, Baudouin C. In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimato-prost in a conjunctival epithelial cell line. Curr Eye Res. 2008; 33: 303-312.
24. Kahook MY, Ammar DA. In vitro toxicity of topical ocular prostaglandin analogs and preservatives on corneal epithelial cells. J Ocul Pharmacol Ther. 2010; 26: 259-263.
25. Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther. 2010; 27: 837-845.
26. DeRosa AJ. Toxic keratopathy. Int Ophthalmol Clin. 1998; 38: 15-22.
27. Chetoni P, Burgalassi S, Monti D, Saettone MF. Ocular toxicity of some corneal penetration enhancers evaluated by electro-physiology measurements on isolated rabbit corneas. Toxicol In Vitro. 2003; 17: 497-504.
28. Nakamura T, Yamada M, Teshima M, et al. Electrophysiological characterization of tight junctional pathway of rabbit cornea treated with ophthalmic ingredients. Biol Pharm Bull. 2007; 30: 2360-2364.
29. Nakashima M, Nakamura T, Teshima M, et al. Breakdown evaluation of corneal epithelial barrier caused by antiallergic eyedrops using an electrophysiologic method. J Ocul Pharmacol Ther. 2008; 24: 43-51.
30. Doucet O, Lanvin M, Thillou C, et al. Reconstituted human corneal epithelium: a new alternative to the Draize eye test for the assessment of the eye irritation potential of chemicals and cosmetic products. Toxicol In Vitro. 2006; 20: 499-512.
31. Pauly A, Meloni M, Brignole-Baudouin F, Warnet JM, Baudouin C. Multiple endpoint analysis of the 3D-reconstituted corneal epithelium after treatment with benzalkonium chloride: early detection of toxic damage. Invest Ophthalmol Vis Sci. 2009; 50: 1644-1652.
32. Khoh-Reiter S, Jessen BA. Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model. BMC Ophthalmol. 2009; 9: 5.
33. Meloni M, Pauly A, Servi BD, Varlet BL, Baudouin C. Occludin gene expression as an early in vitro sign for mild eye irritation assessment. Toxicol In Vitro. 2010; 24: 276-285.
34. Liang H, Pauly A, Riancho L, Baudouin C, Brignole-Baudouin F. Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system. Br J Ophthalmol. 2011; 95: 869-875.
35. Pauly A, Brasnu E, Riancho L, Brignole-Baudouin F, Baudouin C. Multiple endpoint analysis of BAC-preserved and unpre-served antiallergic eye drops on a 3D-reconstituted corneal epithelial model. Mol Vis. 2011; 17: 745-755.
36. Yokoo S, Yamagami S, Usui T, Amano S, Araie M. Human corneal epithelial equivalents for ocular surface reconstruction in a complete serum-free culture system without unknown factors. Invest Ophthalmol Vis Sci. 2008; 49: 2438-2443.
37. Grimes PA, Stone RA, Laties AM, Li W. Carboxyfluorescein. A probe of the blood-ocular barriers with lower membrane permeability than fluorescein. Arch Ophthalmol. 1982; 100: 635-639.
38. Araie M. Carboxyfluorescein. A dye for evaluating the corneal endothelial barrier function in vivo. Exp Eye Res. 1986; 42: 141-150.
39. Araie M. Barrier function of corneal endothelium and the intraocular irrigating solutions. Arch Ophthalmol. 1986; 104: 435-438.
40. Tsuboi S, Pederson JE. Permeability of the isolated dog retinal pigment epithelium to carboxyfluorescein. Invest Ophthal-mol Vis Sci. 1986; 27: 1767-1770.
41. Blair NP, Rusin MM. Blood-retinal barrier permeability to carboxyfluorescein and fluorescein in monkeys. Graefes Arch Clin Exp Ophthalmol. 1986; 224: 419-422.
42. Grimes PA. Carboxyfluorescein transfer across the blood-retinal barrier evaluated by quantitative fluorescence microscopy: comparison with fluorescein. Exp Eye Res. 1988; 46: 769-783.
43. Grimes PA. Carboxyfluorescein distribution in ocular tissues of normal and diabetic rats. Curr Eye Res. 1988; 7: 981-988.
44. Kimura M, Araie M, Koyano S. Movement of carboxyfluor-escein across retinal pigment epithelium-choroid. Exp Eye Res. 1996; 63: 51-56.
45. Lipener C. A randomized clinical comparison of OPTI-FREE EXPRESS and ReNu MultiPLUS multipurpose lens care solutions. Adv Ther. 2009; 26: 435-446.
46. Labbe A, Pauly A, Liang H, et al. Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study. J Ocul Pharmacol Ther. 2006; 22: 267-278.
47. Nair B. Final report on the safety assessment of benzyl alcohol, benzoic acid, and sodium benzoate. Int J Toxicol. 2001; 20: 23-50.
48. Kaur IP, Lal S, Rana C, Kakkar S, Singh H. Ocular preservatives: associated risks and newer options. Cutan Ocul Toxicol. 2009; 28: 93-103.
49. Friedlaender MH, Breshears D, Amoozgar B, Sheardown H, Senchyna M. The dilution of benzalkonium chloride (BAK) in the tear film. Adv Ther. 2006; 23: 835-841.
50. Champeau EEH. Effect of Ophthalmic Preservatives on the Ocular Surface: Conjunctival and Corneal Uptake and Distribution of Benzalkonium Chloride and Chlorhexidine Digluconate. Lubbock, TX.: Dry Eye Institute, Inc; 1986.
51. Uematsu M, Kumagami T, Shimoda K, et al. Influence of alkyl chain length of benzalkonium chloride on acute corneal epithelial toxicity. Cornea. 2010; 29: 1296-1301.